INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
Corporate insider
RL

Rachlin Evan Lockwood

DirectorCIK 0002151678

EDGAR filingsOpen in network
Disclosed transactions9
Buys / sells1 / 0
Max Insider Score49
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
RL
Rachlin Evan LockwoodDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
410.8K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Iambic Therapeutics, Inc.Director · Oct 16, 2026
9
RL
Rachlin Evan LockwoodDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C
—
57.8K sh
Oct 16, 2026
Oct 19, 2026
traded Oct 16, 2026
+3d
SEC FORM 4

Evidence

9
RL
Rachlin Evan LockwoodDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
1.46M sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

17
RL
Rachlin Evan LockwoodDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
410.8K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

49
RL
Rachlin Evan LockwoodDirector
IAMIambic Therapeutics, Inc.
Open-market purchase
BUY$11.50M
718.8K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
RL
Rachlin Evan LockwoodDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
1.15M sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
RL
Rachlin Evan LockwoodDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
57.8K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
RL
Rachlin Evan LockwoodDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
306.7K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
RL
Rachlin Evan LockwoodDirector
IAMIambic Therapeutics, Inc.
Grant or award
A—
20.3K sh
Oct 14, 2026Oct 16, 2026
traded Oct 14, 2026
+2dSEC FORM 4

Evidence